EIF5A2 is a Novel Chemoresistance Gene in Breast Cancer

Overview

Journal Breast Cancer

Specialty Oncology

Date 2014 Mar 19

PMID 24638963

Citations 24

Authors

Yu Liu

Feiya Du

Wei Chen

Minya Yao

Kezhen Lv

Peifen Fu

Affiliations

Soon will be listed here.

Abstract

Background: The eIF5A2 gene (encoding the eukaryotic initiation factor 5A2) located at 3q26 is a putative oncogene that is overexpressed in colon and rectal carcinomas, lung cancer and hepatocellular carcinoma. EIF5A2 overexpression correlates significantly with tumor metastasis and is an adverse prognostic marker. However, eIF-5A2 overexpression in breast cancer and its effect on chemotherapy are unknown.

Methods: We measured eIF-5A2 expression and doxorubicin sensitivity in different human breast cancer cell lines (Bcap-1937, HCC1937, and MCF-7). To investigate a role for eIF-5A2 in chemoresistance, cells were treated with eIF-5A2-siRNA, exposed to various concentrations of doxorubicin, and toxicity was assayed by CCK-8 (cell counting kit).

Results: The eIF-5A2 expression levels varied among breast cancer cells. Higher expression levels correlated with decreased doxorubicin sensitivity. Silencing of eIF-5A2 significantly improved doxorubicin toxicity in all three breast cancer cell lines.

Conclusion: This study shows that eIF-5A2 plays an important role in doxorubicin chemoresistance in breast cancer cells.

Citing Articles

Prognostic value of EIF5A2 in solid tumors: A meta-analysis and bioinformatics analysis.

Fang J, Yu T, Jiang X, Lu Y, Shang X, Shen H Open Med (Wars). 2024; 19(1):20240962.

PMID: 38770178 PMC: 11103163. DOI: 10.1515/med-2024-0962.

Targeting eIF5A2 reduces invasion and reverses chemoresistance in SCC-9 cells .

Gao J, Li P Histol Histopathol. 2023; 39(4):463-470.

PMID: 37334930 DOI: 10.14670/HH-18-637.

Novel roles of RNA-binding proteins in drug resistance of breast cancer: from molecular biology to targeting therapeutics.

Cen Y, Chen L, Liu Z, Lin Q, Fang X, Yao H Cell Death Discov. 2023; 9(1):52.

PMID: 36759501 PMC: 9911762. DOI: 10.1038/s41420-023-01352-x.

High eukaryotic initiation factor 5A2 expression predicts poor prognosis and may participate in the SNHG16/miR-10b-5p/EIF5A2 regulatory axis in head and neck squamous cell carcinoma.

Ye S, Wang D, Jin M, Du J, Chen X, Zhang H J Clin Lab Anal. 2022; 37(1):e24820.

PMID: 36550070 PMC: 9833988. DOI: 10.1002/jcla.24820.

Eukaryotic initiation factor 5A2 mediates hypoxia-induced autophagy and cisplatin resistance.

Xu G, Chen H, Wu S, Chen J, Zhang S, Shao G Cell Death Dis. 2022; 13(8):683.

PMID: 35931669 PMC: 9356061. DOI: 10.1038/s41419-022-05033-y.